5月29日,君实生物(688180/01877)发布公告,根据募投项目的进展,决定对2022年度向特定对象发行A股股票募集资金投资项目中的“创新药研发项目”进行部分临床试验子项目及其募集资金投资金额的调整,募集资金投资总金额保持不变。公告中提到,公司获得向特定对象发行7000万股人民币普通股,发行价格为53.95元,募集资金总额为37.77亿元,实际到账金额为37.59亿元。此次变更将新增多个临床...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.